Embecta (EMBC) Q4 2024 earnings summary

Executive summary

• Achieved strategic milestones post-spin, including ERP implementation for 98% of revenue, exclusive contracts, and new product launches.

• Exceeded 2024 financial expectations despite macroeconomic headwinds, with a 1.3% constant currency adjusted revenue CAGR and 31.4% adjusted EBITDA margin.

• Discontinued insulin patch pump program and announced restructuring to streamline operations, reduce costs, and enhance profitability.

• Initiated debt paydown plan and published ESG strategy report.

• Launched small-pack GLP-1 pen needle in Germany, with further market expansion under evaluation.

Financial highlights

• Q4 adjusted revenues: $290.2M, up 4.1% year-over-year; full-year adjusted revenues: $1,127.2M, up 1.1%.

• Q4 adjusted gross margin: 61.4% (down from 64.8%); full-year adjusted gross margin: 65.7% (down from 67.0%).

• Q4 adjusted net income: $25.9M, EPS $0.45; full-year adjusted net income: $143.1M, EPS $2.45.

• Q4 adjusted EBITDA: $73.0M (25.2% margin); full-year adjusted EBITDA: $353.4M (31.4% margin).

• Ended Q4 with $274M cash and net leverage of 3.8x.

Outlook and guidance

• 2025 adjusted constant currency revenue expected to decline 1%–2.5% year-over-year; as-reported revenue guidance: $1.093B–$1.11B.

• 2025 adjusted gross margin expected at 63.25%–64.25%; adjusted operating margin 29%–30%.

• 2025 adjusted EPS guidance: $2.70–$2.90; adjusted EBITDA margin: 35.5%–36.5%.

• Plans to repay ~$110M in debt in 2025; net leverage expected to fall to ~3x by year-end.

• Guidance reflects impact of Italian payback accruals and FX headwinds.